Optimal Treatment of PAH

Slides:



Advertisements
Similar presentations
Upfront Combination Therapy vs Step-Up Approach for PAH:
Advertisements

Clinical use of PAH drugs based on functional class
Endocrine Combinations in HR-Positive MBC: The Future Is Now
Exploring Early Combination Therapy in PAH
Monitoring and Modifying Treatment in PAH
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Optimizing Therapy for Osteoarthritis
Risk Stratification in PAH: What Do the Latest Data Suggest?
A Paradigm Shift in PAH.
An Update on Oral Prostanoids: Advancing Care for PAH?
Cardiogenic Shock.
Goals of Therapy for Patients With UC
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
UNDERSTANDING RISK STRATIFICATION IN PAH:
The Latest Data on Oral Prostacyclin Therapy in PAH
All About PAH:.
Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
The Evolving Role of Immunotherapy in NSCLC
PAH Therapy Revisited.
PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
An Update on PCSK9 Inhibitors
Improving Risk Assessment and Early Diagnosis in PAH
Updates in Pulmonary Arterial Hypertension
Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy
Cardiovascular Comorbidities A Common Occurrence With COPD
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
WHO Clinical Classification of PH Complex Cases in PH.
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
Evolving Science of PAH Treatment
Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Risk Assessment in PAH.
2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.
Examining the Latest Evidence in PAH
Insulin Use in Primary Care: Practice Challenges
Optimizing Frontline Care for Older Patients With Multiple Myeloma
Battling Constipation
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
Oral Prostanoids and PAH
Navigating Treatment Options in PAH
Preventing Clinical Events in PAH
PAH and Prostacyclin Pathways in Focus
PAH-Related Morbidity as a Predictor of Mortality
PAH Treatment.
Cancer-Associated Thrombosis
Pulmonary Arterial Hypertension and Connective Tissue Disease
What's New in PAH?.
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
Oral Prostacyclin Pathway Agents in PAH
Pulmonary Hypertension Updates From 2018
Incorporating Prostacyclins Into Practice
Perspective on the Multidisciplinary Management of PAH
Patient Stories in PAH: Sequential Therapy in a FC II Patient
Assessing the Burden of Hyperkalemia
An Update on PCSK9 Inhibitors
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Prostacyclin Pathway Agents in Action
Transitioning Therapy in PAH: Practical Strategies and Considerations
Assessing the Burden of Hyperkalemia
Incorporating New PAH Treatments Into Clinical Practice
PAH Pathways: What Do the Data Tell Us?”
Clinical Comparisons in CTEPH
Pulmonary Arterial Hypertension and Hospitalizations
Merging the Art and Science of Managing nOH in Clinical Practice
What's New in PAH?.
My PAH Patient.
Presentation transcript:

Optimal Treatment of PAH

Endothelial Dysfunction in PAH

Treatment Algorithm for PAH

Recommendations for General Measures

Recommendations for Supportive Therapy

Treatment Algorithm for PAH

Risk Assessment in PAH

Treatment Algorithm for PAH

Monotherapy Recommendations for PAH

Initial Combination Therapy Recommendations for PAH

Sequential Combination Therapy Recommendations for PAH

The Rationale for Combination Therapy

Expert Consensus Recommendations for Combination Therapy Have Improved With Increasing Experience

An Evolving Paradigm From Sequential to Initial Upfront Combination Therapy

AMBITION Study Design

AMBITION Results

Initial Dual Oral Combination Therapy for PAH Experience of the French Network

Initial Dual Oral Combination Therapy for PAH Experience of the French Network

Selexipag

GRIPHON Selexipag for the Treatment of PAH

GRIPHON Primary End Point

Looking Forward

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)